“praluent” Archives

in
Entry Author Date Location
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests 09/25/19 New York
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing 09/02/19 New York
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More 08/30/19 National
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.) 08/26/19 National
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More 05/03/19 National
Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark 03/01/19 National
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More 02/15/19 National
Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60% 02/11/19 New York
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More 05/04/18 National
Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price 05/01/18 New York
Regeneron to Slash Price of Cholesterol Drug After Showing It Saved Lives 03/10/18 New York
Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More 03/09/18 National
Esperion Touts Low Cholesterol Drug Price, But Not All Data are Ready 03/07/18 Detroit Ann Arbor
Medicines Co. Sells Infectious Disease Drugs, Focusing on PCSK9 11/29/17 New York
Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing 09/11/17 New York
70% Repatha Cut? Amgen Counters With Own Study To Justify Price 08/23/17 National
Amgen’s Heart Data Don’t Impress Drug-Price Evaluation Group 06/13/17 San Francisco
The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug 04/26/17 New York
FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price 03/28/17 New York
With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work 03/17/17 San Francisco
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More 02/10/17 National
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study 11/17/16 New York
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 11/15/16 New York
In Cholesterol Drug Price Fight, Real Message Is “Wait Til Next Year” 08/18/16 National
Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease 05/28/16 New York
East Coast Biotech Roundup: NY Bio, Gender Gap, Zafgen, PureTech & More 05/12/16 Boston
Making the Price Right: Ideas To Change Drug Costs Gain Momentum 04/05/16 National
Page 1 of 2 next page »